Amarin Corp Plc (AMRN)

[sts66]

It's not even an official decision yet, still needs to be approved by the EU:

The review of omega-3 fatty acid medicines was started on 22 March 2018 at the request of the Swedish medicines agency under Article 31 of Directive 2001/83/EC.

The review has been carried out by the Committee for Medicinal Products for Human Use (CHMP), responsible for questions concerning medicines for human use, which has adopted the Agency’s opinion. The CHMP opinion will now be forwarded to the European Commission, which will issue a final legally binding decision applicable in all EU Member States.